Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Select Medical Holdings (SEM) Cost of Revenue (2018 - 2025)

Select Medical Holdings (SEM) has disclosed Cost of Revenue for 8 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 6.44% to $1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 billion, a 5.93% increase, with the full-year FY2025 number at $4.8 billion, up 5.93% from a year prior.
  • Cost of Revenue was $1.3 billion for Q4 2025 at Select Medical Holdings, up from $1.2 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $1.4 billion in Q1 2022 to a low of $16.3 million in Q4 2022.
  • A 5-year average of $1.2 billion and a median of $1.2 billion in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 98.84% in 2022, then surged 6485.7% in 2023.
  • Select Medical Holdings' Cost of Revenue stood at $1.4 billion in 2021, then plummeted by 98.84% to $16.3 million in 2022, then soared by 6485.7% to $1.1 billion in 2023, then increased by 9.41% to $1.2 billion in 2024, then grew by 6.44% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for SEM's Cost of Revenue are $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).